Navigation Links
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
Date:12/3/2010

es, statistical superiority of NP002 over placebo were observed in a variety of physician- and patient-rated PD efficacy outcome measures relating to dyskinesias.

Abraham Lieberman, MD, the study's principal investigator and Director of the Muhammad Ali Parkinson's Center, commented, "NP002 represents an innovative approach to a common side effect in treating Parkinson's disease and has opened up new ideas on how to approach dyskinesias.  The early study results of NP002 in patients with Parkinson's show promising trends in reducing dyskinesias and in improving gait.  I am encouraged by these results and believe they provide a key piece in understanding and addressing the mechanism of dyskinesias in many of our patients with Parkinson's disease."

J. William Langston, MD, Founder, CEO and Scientific Director of the Parkinson's Institute, stated, "It's impressive that the NP002 study data were encouraging across several scales used to measure dyskinesias.  In particular, the study showed a significant trend in improvement in the objective UDRS scale and statistically significant results on the PGIC scale, which measures how patients feel overall, suggesting an improvement in quality of life.  We are very excited to see this work progress to Phase 2 trials based on these encouraging data."

Carrolee Barlow, MD, PhD, CSO and CMO of BrainCells, Inc., and scientific advisor to Neuraltus on the NP002 program, stated, "Patients with Parkinson's disease currently have no therapeutic options to address the dyskinesias caused by levodopa treatment.  The clinical study demonstrated a clinically important improvement in dyskinesia symptoms that could be detected by both clinicians and patients.  The data are compelling and provide a breakthrough for this condition."

The Phase 1/2 data are the second clinical program results reported by Neuraltus this week, following announcement of clinical results for NP001, which showed
'/>"/>

SOURCE Neuraltus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
3. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
4. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
5. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
6. Onyx Pharmaceuticals Announces December 2010 Investor Events
7. Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
8. Prolong Pharmaceuticals Boosts Executive Team
9. Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
10. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
11. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
...  Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... granted a positive opinion for conditional approval from ... Products for Human Use ("CHMP"). Based on the ... authorization for Pixuvri should be granted by the ...
...  A new look at the three most highly regarded ... of its kind to consider long-term cost and quality ... prostatectomy surgery and brachytherapy to be less expensive and ... the treatment of prostate cancer . ...
Cached Medicine Technology:European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 2European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 3European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 4European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™ 5Prostate Cancer Treatment Options Go Head-to-Head 2Prostate Cancer Treatment Options Go Head-to-Head 3
(Date:4/22/2014)... 22, 2014: The Association for Molecular Pathology (AMP) ... of Molecular Diagnostics on recommendations for a ... master,s levels of education. The report was prepared ... Force of the AMP Training and Education Committee. ... of educating future medical laboratory scientists appropriately in ...
(Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... 10 Americans support mandated coverage of birth control medications, ... the University of Michigan Health System. , Women, blacks, ... at home, and adults with private or public insurance ... universal coverage of birth control medications, according to the ... American Medical Association ( JAMA ). , Individuals ...
(Date:4/22/2014)... German . Scientists ... Vienna and the Medical University of Vienna, together with colleagues ... RNA, such as viral genetic information, is prevented from entering ... viral infection, the protein ADAR1 moves from the cell nucleus ... inhibit reproduction of the virus. But how is the human ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... government, through the U.S. Agency for International Development (USAID), is ... Assistance Response Team (DART) to help combat the cholera outbreak ... than $4.6 million for emergency water, sanitation, and hygiene program ... , This new funding will provide additional ...
... 11 Mary Beth Bolton, MD, FACP, a Detroit internal ... by the Michigan State Medical Society (MSMS). , ... Chief Medical Officer with Health Alliance Plan (HAP) since 2000, ... career-long commitment to improving primary patient care through increasing access, ...
... to "Tell Their Stories" , , ... that healthcare reform will be a top priority in his ... serve as health and human services secretary, is the leader ... to help with reform efforts by sharing their healthcare experiences ...
... million people die every year from infectious diseases, ... The discovery of penicillin to treat bacterial ... previously incurable virus diseases such as polio and ... mid-20th century. , Recently, spectacular advances in medical ...
... company, announced today that beginning January 1, 2009, ... for incomplete spinal cord injury patients suffering from ... Medicare and Medicaid Services (CMS) establishes a new ... devices including the NESS L300™ Foot Drop System. ...
... GLENVIEW, IL, Dec. 11, 2008 Federal funding for pain research ... according to a new study published in The Journal of ... only 0.6 percent of all grants awarded by the National Institutes ... the U.S. , "This startling finding shows the government,s ...
Cached Medicine News:Health News:USAID Provides Additional $6.2M for Zimbabwe Cholera Outbreak 2Health News:Mary Beth Bolton, MD, Named 'Woman Physician of the Year' by Michigan State Medical Society 2Health News:Hospice Community Encouraged to Respond to Daschle Request to Participate in Information Gathering about Healthcare Concerns 2Health News:Mathematical models of adaptive immunity 2Health News:Mathematical models of adaptive immunity 3Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Study shows major pain research funding decline at NIH 2
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... large number of mobile, modular and transportable ... fleet. The labs are typically leased to ... The Cath Lab Leasing Company allows hospitals ... upgrading existing equipment, initiating a new service ...
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: